Can lamivudine dolutegravir cause weight gain?

In April 2019, lamivudine dolutegravir tablets were approved as the first complete dual-drug antiretroviral therapy (ART) regimen for adults with untreated HIV, or to replace existing regimens for the following patients: Viral suppression (HIV-1 RNAless than 50 copies per milliliter), Stable antiretroviral therapy with no history of treatment failure, There are no known substitutions associated with resistance to Dovatoindividual components.

Clinical studies have shown that lamivudine dolutegravir tablets weight increased from 2.4 to 6kg (5.3 to 13.2lbs) after one year of treatment. In a randomized trial study published in 2019, clinical infectious disease researchers looked at the use of integrase inhibitors such as dolutegravir (inDovato found) or bictegravir (found in Biktarvy) weight gain. The researchers found that patients taking integrase inhibitors gained significantly more weight (3.24kg) than those taking NNRTIs or protease inhibitors. Compared with the beginning of the study, the body weight increased significantly by more than 10%. dolutegravirThe average weight gain over 96 weeks was 4.07kg ( The 95%confidence interval is 3.5 to 4.6kg), which equates to an average weight gain of about 9 pounds.

A study conducted in the United States from 2007to2016 was published in Clinical Infectious Disease Researchers Investigated1,152Whether weight gain differed among 152 people living with HIV who had not received prior treatment (termed "treatment-naïve"). The INSTIbased regimen was compared with other ART regimens. Among participants, 351 started treatment with an INSTI-based regimen (135dolutegravir, 153namedelvitegravir and 63namedraltegravir), of which 86% were male and 49% were white. Body mass index at the start of treatment was 25.1kg/m². Across all study sites, the dolutegravir group had the highest weight gain, with significant differences found. At 18 months, the mean weight gain in the dolutegravir group was 6kg (13.2lbs) compared with NNRTIs The mean weight gain was 2.6kg (5.7lbs) and 0.5kg (1.1lbs). withINSTI raltegravir (3.4kg) and protease inhibitor (4.1kg) People taking dolutegravir gained more weight at 18 months than those taking dolutegravir, although these differences were not statistically significant. It was concluded that patients who first started treatment with a dolutegravir-based regimen gained significantly more weight at 18 months than patients who started NNRTI and elvitegravirbased regimens.

Indian pharmacy retail price per box300around 100 yuan. If you want to get more high-quality information, you can contact YaDE. YaDE will do its best to learn more about high-quality overseas drugs for you.